Results

1–4 of 4 results for subretinal gene therapy

Interim Subretinal Gene Therapy Safety Results in Two Phase 1/2 Open-label, Dose-Escalation Clinical Trials to Treat Achromatopsia
Lejla Vajzovic, MD, FASRS
Annual Meeting Talks
2022
Subretinal Gene Therapy Drug AGTC-501 for X-Linked Retinitis Pigmentosa: Phase 2 Randomized Controlled Masked Multicenter Clinical Trial (Skyline) Interim Safety Results
On Demand Cases, Courses, and Papers
2022
Intraoperative Use of Microscope-Integrated OCT for Subretinal Gene Therapy
Ninel Z. Gregori, MD
Annual Meeting Talks
2018
Subretinal Gene Therapy Delivery
Szilárd Kiss, MD
Updates from the Field
2018